Navigation Links
Horizon Therapeutics Announces Corporate Relocation to the Chicago Area

PALO ALTO, Calif., July 31 /PRNewswire/ -- Horizon Therapeutics, Inc., a privately held biopharmaceutical company, today announced that it will move its corporate headquarters from Palo Alto, Calif. to the Chicago, Ill., area.

"The relocation will help us continue growing, extend our opportunities for partnerships and conduct business in one of the most dynamic markets in the country," said Timothy P. Walbert, president and chief executive officer of Horizon. "Chicago has all the elements to become a major life-science hub, but it's still rivaled by its bi-coastal counterparts. We wanted to relocate here to be an integral part of the market growth as well as leverage the existing market opportunities to grow our business."

The company will begin operations in its new headquarters in early August at the Illinois Science and Technology Park in Skokie, Ill., which formerly housed the Searle and then subsequently Pharmacia and Pfizer research and development offices. Horizon has approximately 50 full-time employees and consultants.

Mr. Walbert, who was recently named president and chief executive officer of Horizon and has approximately 20 years of proven experience launching and commercializing blockbuster drugs in the pain and arthritis fields, is focusing the Company's efforts on meeting the needs of arthritis and pain sufferers, specifically with its investigational compound HZT-501, a novel proprietary formulation of ibuprofen combined with famotidine in a single pill currently in Phase 3 clinical trials. Because approximately 25 percent of NSAID users may develop stomach ulcers, HZT-501 may offer patients effective pain relief with the confidence of GI-protection. Horizon expects to have data from the HZT-501 Phase 3 trials in fourth quarter of this year.

About Horizon Therapeutics

Horizon Therapeutics, Inc. is a late-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of mild-to-moderate pain and arthritis. Horizon's clinical portfolio includes innovative combination therapies in early- and late-stage development that are designed to improve safety, efficacy and patient compliance. For more information about the company and its products, please visit

SOURCE Horizon Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Out beyond the horizon
2. Out beyond the horizon
3. BioHorizons Announces Agreement to Purchase Implant Logic Systems
4. Biotech Pioneer William J. Rutter to Deliver Keynote at 2008 RAPS Horizons Conference
5. Caliper Life Sciences Forms Alliance With Horizon Discovery to Provide Enhanced Solutions for Cancer Research Based on Isogenic Cell Lines
6. BioHorizons Announces the Purchase of Implant Logic Systems
7. BioHorizons Global Symposium 2008 Combines Record Attendance with Groundbreaking Technology
8. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
9. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
10. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
11. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015  PharmAthene, Inc. (NYSE ... has adopted a stockholder rights plan (Rights Plan) in ... operating loss carryforwards (NOLs) under Section 382 of the ... --> PharmAthene,s use of its NOLs could ... change" as defined in Section 382 of the Code. ...
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. ... Gorman , President and CEO of Neurocrine Biosciences, will ... Conference in New York . ... visit the website approximately 5 minutes prior to the ... replay of the presentation will be available on the ...
(Date:11/25/2015)... November 25, 2015 The ... is a professional and in-depth study on the ...      (Logo: ) , ... industry including definitions, classifications, applications and industry chain ... the international markets including development trends, competitive landscape ...
(Date:11/24/2015)... 24, 2015 Cepheid (NASDAQ: CPHD ) ... the following conference, and invited investors to participate via ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern ... New York, NY      Tuesday, December 1, ...
Breaking Biology Technology:
(Date:10/27/2015)... 27, 2015 In the present market scenario, ... for various industry verticals such as banking, healthcare, defense, ... growing demand for secure & simplified access control and ... as hacking of bank accounts, misuse of users, , ... as PC,s, laptops, and smartphones are expected to provide ...
(Date:10/26/2015)... and LAS VEGAS , Oct. ... Labs , an innovator in modern authentication and a ... announced the launch of its latest version of the ... enabling organizations to use standards-based authentication that supports existing ... S3 Authentication Suite is ideal for organizations deploying customer-facing ...
(Date:10/22/2015)... -- Aware, Inc. (NASDAQ: AWRE ), a leading supplier of biometrics ... ended September 30, 2015.  --> ... million, a decrease of 33% compared to $6.0 million in the ... 2015 was $2.2 million, or $0.10 per diluted share, which compared ... period a year ago.  --> ...
Breaking Biology News(10 mins):